-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
-
Summary
-
BriaCell Therapeutics Corp. quarterly/annual Net Cash Provided by (Used in) Financing Activities history and growth rate from Q3 2022 to Q3 2024.
- BriaCell Therapeutics Corp. Net Cash Provided by (Used in) Financing Activities for the quarter ending October 31, 2024 was $12M.
- BriaCell Therapeutics Corp. annual Net Cash Provided by (Used in) Financing Activities for 2024 was $4.42M, a 11.8% increase from 2023.
- BriaCell Therapeutics Corp. annual Net Cash Provided by (Used in) Financing Activities for 2023 was $3.95M.
- BriaCell Therapeutics Corp. annual Net Cash Provided by (Used in) Financing Activities for 2022 was -$3.74M, a 106% decline from 2021.